RNA-based therapeutics, specifically antisense oligonucleotides inducing exon skipping, are currently among the most promising therapies in development for DMD. In detail have the antisense oligonucleotides capable of skip an exon and thereby correct the reading frame of the DMD transcripts with the aim of synthesis of a new protein dystrophin. Different mutations in the gene require different oligonucleotide drugs.
You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at Kaiser health news.
About DMD and exon skippingDuchenne muscular dystrophy is a severely debilitating childhood neuromuscular disease that affects 1 in 3500 newborn boys, the young patients suffer from a progressive loss of muscle strength due to the absence of the protein dystrophin, often making them wheelchair before age. 12 tied. Most patients die in early adulthood due to respiratory and cardiac failure. Is no treatment to prevent the eventual fatal outcome. The disease is caused by mutations in the DMD gene, which. Absence of the dystrophin protein for the integrity for the integrity of the muscle fiber membranes.. Open-label 7.5M milestone payment as part of their program with GlaxoSmithKline in Duchenne muscular dystrophy?Prosensa modulate the Dutch biopharmaceutical company focusing on RNA therapeutics, today announced that it 7.5m 7.5m milestone payment from GlaxoSmithKline as a? to achieve a result, a data milestone in its Phase IIa open label extension trial of GSK2402968 , developed to Duchenne muscular dystrophy under its agreement with GSK to treat.On central nervous to myelin membranes are made with cells mentioned oligodendrocytes. Evenly distributed along distributed uniformly along axons – the long, thread-like expansion of neurons carry nervous impulses – so that the diaphragms that Cover the nerve fibers such millions of microscopic plays electrical tape able cover the axons completely and uniformly. Membranes are are near the end of fetal development , and indeed for some time to after birth.
Food and Drug Administration is deleted to begin enrolling patients. ALN – SFPS, a RNAi therapeutic for the treatment from hepatic Krebs , including hepatocellular carcinoma and other solid tumors with hepatic involvement, has two small interfering RNAs in in a lipid nanoparticles with Tekmira Pharmaceuticals Corporation formulated. ALN – VSP should aim two genes supercritical the growth and the development of cancerous: kinesin spindle protein or KSP, required to tumor cell proliferation and vascular endothelial growth factor, or VEGF, the tumor growth is required. Preclinical data in mouse tumor model studies have shown robust activity of ALN – VSPs , including suppression of targeted genes, demonstration activities of an RNAi mechanism of tumor reduction and extension of survival times.